The role of miRNAs in cardiovascular disease risk factors

Atherosclerosis

Volumn 254, Issue , 2016, Pages 271-281

  Jones Buie, Joy N ^a   Goodwin, Andrew J ^b   Cook, James A ^a   Halushka, Perry V ^a   Fan, Hongkuan ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cardiovascular disease; Coronary artery disease; miRNA; Review; Risk factors

Indexed keywords

AGENTS AFFECTING NUCLEIC ACID METABOLISM; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MICRORNA; TOBACCO SMOKE;

BASIC RESEARCH; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL COMMUNICATION; CLINICAL RESEARCH; DIABETES MELLITUS; DRUG TARGETING; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID HOMEOSTASIS; LIPID METABOLISM; MOLECULAR PATHOLOGY; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; RNA SYNTHESIS; TOBACCO USE; TRANSLATIONAL RESEARCH; ANIMAL; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; GENETICS; HOMEOSTASIS; METABOLISM; MOUSE; RISK FACTOR; SMOKING; TOBACCO; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; CELL COMMUNICATION; CHOLESTEROL; CORONARY ARTERY DISEASE; HOMEOSTASIS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MICE; MICRORNAS; OBESITY; RISK FACTORS; SMOKING; TOBACCO; TREATMENT OUTCOME;

EID: 84993977938     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.09.067     Document Type: Review

References (146)

1. [1] Gouda, H.N., Critchley, J., Powles, J., Capewell, S., Why choice of metric matters in public health analyses: a case study of the attribution of credit for the decline in coronary heart disease mortality in the US and other populations. BMC Public Health., 12, 2012, 88.
2. [2] Lawlor, D.A., Smith, G.D., Leon, D.A., Sterne, J.A., Ebrahim, S., Secular trends in mortality by stroke subtype in the 20th century: a retrospective analysis. Lancet 360:9348 (2002), 1818–1823.
3. [3] Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131:4 (2015), e29–322.
4. [4] Green, E.D., Watson, J.D., Collins, F.S., Human genome project: twenty-five years of big biology. Nature 526:7571 (2015), 29–31.
5. [5] Ozaki, K., Genetic background of acute coronary syndrome. Nihon Rinsho. 68:4 (2010), 615–620.
6. [6] Sui, W., Liu, F., Chen, J., Ou, M., Dai, Y., Microarray technology for analysis of microRNA expression in renal biopsies of lupus nephritis patients. Methods Mol. Biol. 1134 (2014), 211–220.
7. [7] Abi Khalil, C., The emerging role of epigenetics in cardiovascular disease. Ther. Adv. Chronic Dis. 5:4 (2014), 178–187.
8. [8] Lagos-Quintana, M., Rauhut, R., Lendeckel, W., Tuschl, T., Identification of novel genes coding for small expressed RNAs. Science 294:5543 (2001), 853–858.
9. [9] Bartel, D.P., Chen, C.Z., Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet. 5:5 (2004), 396–400.
10. [10] Kozomara, A., Griffiths-Jones, S., miRBase: integrating microRNA annotation and deep-sequencing data. Nucl. Acids Res. 39:Database issue (2011), D152–D157.
11. [11] Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., Lotvall, J.O., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9:6 (2007), 654–659.
12. [12] Lee, R.C., Feinbaum, R.L., Ambros, V., The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:5 (1993), 843–854.
13. [13] Wightman, B., Ha, I., Ruvkun, G., Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75:5 (1993), 855–862.
14. [14] Reinhart, B.J., Slack, F.J., Basson, M., et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:6772 (2000), 901–906.
15. [15] Lau, N.C., Lim, L.P., Weinstein, E.G., Bartel, D.P., An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294:5543 (2001), 858–862.
16. [16] Lee, Y., Jeon, K., Lee, J.T., Kim, S., Kim, V.N., MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21:17 (2002), 4663–4670.
17. [17] Han, J., Lee, Y., Yeom, K.H., Kim, Y.K., Jin, H., Kim, V.N., The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18:24 (2004), 3016–3027.
18. [18] Lund, E., Guttinger, S., Calado, A., Dahlberg, J.E., Kutay, U., Nuclear export of microRNA precursors. Science 303:5654 (2004), 95–98.
19. [19] Ketting, R.F., Fischer, S.E., Bernstein, E., Sijen, T., Hannon, G.J., Plasterk, R.H., Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15:20 (2001), 2654–2659.
20. [20] Hauptmann, J., Meister, G., Argonaute regulation: two roads to the same destination. Dev. Cell. 25:6 (2013), 553–554.
21. [21] Pratt, A.J., MacRae, I.J., The RNA-induced silencing complex: a versatile gene-silencing machine. J. Biol. Chem. 284:27 (2009), 17897–17901.
22. [22] Olson, E.N., MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci. Transl. Med., 6(239), 2014 239ps233.
23. [23] Lee, Y., El Andaloussi, S., Wood, M.J., Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum. Mol. Genet. 21:R1 (2012), R125–R134.
24. [24] Mitchell, P.S., Parkin, R.K., Kroh, E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105:30 (2008), 10513–10518.
25. [25] Arroyo, J.D., Chevillet, J.R., Kroh, E.M., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 108:12 (2011), 5003–5008.
26. [26] Wagner, J., Riwanto, M., Besler, C., et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler. Thromb. Vasc. Biol. 33:6 (2013), 1392–1400.
27. [27] Jansen, F., Yang, X., Hoelscher, M., et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 128:18 (2013), 2026–2038.
28. [28] Emde, A., Hornstein, E., miRNAs at the interface of cellular stress and disease. EMBO J. 33:13 (2014), 1428–1437.
29. [29] Rader, D.J., Daugherty, A., Translating molecular discoveries into new therapies for atherosclerosis. Nature 451:7181 (2008), 904–913.
30. [30] Feinberg, M.W., Moore, K.J., MicroRNA regulation of atherosclerosis. Circ. Res. 118:4 (2016), 703–720.
31. [31] Gupta, S.P., Gupta, M.S., Moga, R.L., Smoking as a coronary risk factor–comparative evaluation of cigarette paper and bidi leaf. Indian J. Med. Sci. 34:7 (1980), 163–167.
32. [32] Huxley, R.R., Woodward, M., Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 378:9799 (2011), 1297–1305.
33. [33] Hoffmann, D., Hoffmann, I., El-Bayoumy, K., The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem. Res. Toxicol. 14:7 (2001), 767–790.
34. [34] Tang, G.J., Wang, H.Y., Wang, J.Y., et al. Novel role of AMP-activated protein kinase signaling in cigarette smoke induction of IL-8 in human lung epithelial cells and lung inflammation in mice. Free Radic. Biol. Med. 50:11 (2011), 1492–1502.
35. [35] Csordas, A., Bernhard, D., The biology behind the atherothrombotic effects of cigarette smoke. Nat. Rev. Cardiol. 10:4 (2013), 219–230.
36. [36] Chamorro-Jorganes, A., Araldi, E., Suarez, Y., MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. Pharmacol. Res. 75 (2013), 15–27.
37. [37] Wang, S., Aurora, A.B., Johnson, B.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell. 15:2 (2008), 261–271.
38. [38] Fish, J.E., Santoro, M.M., Morton, S.U., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell. 15:2 (2008), 272–284.
39. [39] Harris, T.A., Yamakuchi, M., Ferlito, M., Mendell, J.T., Lowenstein, C.J., MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 105:5 (2008), 1516–1521.
40. [40] Yang, J., Lan, H., Huang, X., Liu, B., Tong, Y., MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One., 7(8), 2012, e42978.
41. [41] Schober, A., Nazari-Jahantigh, M., Wei, Y., et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat. Med. 20:4 (2014), 368–376.
42. [42] Takahashi, K., Yokota, S., Tatsumi, N., Fukami, T., Yokoi, T., Nakajima, M., Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicol. Appl. Pharmacol. 272:1 (2013), 154–160.
43. [43] Chen, C., Wang, Y., Yang, S., et al. miR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF. J. Cell Mol. Med. 19:5 (2015), 970–985.
44. [44] Yu, X.Y., Chen, J.Y., Zheng, Z.W., et al. Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention. EuroIntervention 9:5 (2013), 546–554.
45. [45] Kalscheuer, S., Zhang, X., Zeng, Y., Upadhyaya, P., Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 29:12 (2008), 2394–2399.
46. [46] Zeng, Y., Zhang, X., Kang, K., et al. MicroRNA-223 attenuates hypoxia-induced vascular remodeling by targeting RhoB/MLC2 in pulmonary arterial smooth muscle cells. Sci. Rep., 6, 2016, 24900.
47. [47] Bennett, M.R., Sinha, S., Owens, G.K., Vascular smooth muscle cells in atherosclerosis. Circ. Res. 118:4 (2016), 692–702.
48. [48] Herberth, G., Bauer, M., Gasch, M., et al. Maternal and cord blood miR-223 expression associates with prenatal tobacco smoke exposure and low regulatory T-cell numbers. J. Allergy Clin. Immunol. 133:2 (2014), 543–550.
49. [49] Badrnya, S., Baumgartner, R., Assinger, A., Smoking alters circulating plasma microvesicle pattern and microRNA signatures. Thromb. Haemost. 112:1 (2014), 128–136.
50. [50] Duan, X., Zhan, Q., Song, B., et al. Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke. J. Diabetes Complicat. 28:5 (2014), 705–710.
51. [51] Izzotti, A., Calin, G.A., Arrigo, P., Steele, V.E., Croce, C.M., De Flora, S., Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 23:3 (2009), 806–812.
52. [52] Haneklaus, M., Gerlic, M., O'Neill, L.A., Masters, S.L., miR-223: infection, inflammation and cancer. J. Intern Med. 274:3 (2013), 215–226.
53. [53] Heistad, D.D., Baumbach, G.L., Faraci, F.M., Armstrong, M.L., Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. J. Hum. Hypertens. 9:6 (1995), 449–453.
54. [54] Nwankwo, T., Yoon, S.S., Burt, V., Gu, Q., Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. 133 (2013), 1–8.
55. [55] Goren, Y., Kushnir, M., Zafrir, B., Tabak, S., Lewis, B.S., Amir, O., Serum levels of microRNAs in patients with heart failure. Eur. J. Heart Fail. 14:2 (2012), 147–154.
56. [56] Wang, X.H., Qian, R.Z., Zhang, W., Chen, S.F., Jin, H.M., Hu, R.M., MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 36:2 (2009), 181–188.
57. [57] Ling, S., Nanhwan, M., Qian, J., et al. Modulation of microRNAs in hypertension-induced arterial remodeling through the beta1 and beta3-adrenoreceptor pathways. J. Mol. Cell Cardiol. 65 (2013), 127–136.
58. [58] Yin, Z., Zhao, Y., Li, H., et al. miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway. Aging (Albany NY) 8:1 (2016), 192–207.
59. [59] Vakili, B.A., Okin, P.M., Devereux, R.B., Prognostic implications of left ventricular hypertrophy. Am. Heart J. 141:3 (2001), 334–341.
60. [60] Callis, T.E., Pandya, K., Seok, H.Y., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119:9 (2009), 2772–2786.
61. [61] Wang, J., Pei, Y., Zhong, Y., Jiang, S., Shao, J., Gong, J., Altered serum microRNAs as novel diagnostic biomarkers for atypical coronary artery disease. PLoS One., 9(9), 2014, e107012.
62. [62] Montgomery, R.L., Hullinger, T.G., Semus, H.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124:14 (2011), 1537–1547.
63. [63] van Rooij, E., Sutherland, L.B., Qi, X., Richardson, J.A., Hill, J., Olson, E.N., Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316:5824 (2007), 575–579.
64. [64] Dickinson, B., Zhang, Y., Petrick, J.S., Heck, G., Ivashuta, S., Marshall, W.S., Lack of detectable oral bioavailability of plant microRNAs after feeding in mice. Nat. Biotechnol. 31:11 (2013), 965–967.
65. [65] Dickinson, B.A., Semus, H.M., Montgomery, R.L., et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur. J. Heart Fail. 15:6 (2013), 650–659.
66. [66] Lin, L., Zheng, Y., Tu, Y., et al. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2. Hum. Pathol. 46:7 (2015), 971–980.
67. [67] Expert Panel on Detection Evaluation, and Treatment Of High Blood Cholesterol in Adults, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:19 (2001), 2486–2497.
68. [68] Sekine, S., Ogawa, R., Ito, R., et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 136:7 (2009), 2304–2315 e2301–2304.
69. [69] Rotllan, N., Price, N., Pati, P., Goedeke, L., Fernandez-Hernando, C., microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis 246 (2016), 352–360.
70. [70] Willeit, P., Skroblin, P., Kiechl, S., Fernandez-Hernando, C., Mayr, M., Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?. Eur. Heart J. 112:4 (2016), 595–600.
71. [71] Cheng, A.Y., Leiter, L.A., Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. Curr. Opin. Cardiol. 21:4 (2006), 400–404.
72. [72] Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., Tuschl, T., Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12:9 (2002), 735–739.
73. [73] Gao, W., He, H.W., Wang, Z.M., et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis., 11, 2012, 55.
74. [74] Krutzfeldt, J., Rajewsky, N., Braich, R., et al. Silencing of microRNAs In vivo with 'antagomirs'. Nature 438:7068 (2005), 685–689.
75. [75] Elmen, J., Lindow, M., Silahtaroglu, A., et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucl. Acids Res. 36:4 (2008), 1153–1162.
76. [76] Esau, C., Davis, S., Murray, S.F., et al. miR-122 regulation of lipid metabolism revealed by In vivo antisense targeting. Cell Metab. 3:2 (2006), 87–98.
77. [77] Hsu, S.H., Wang, B., Kota, J., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122:8 (2012), 2871–2883.
78. [78] Takeuchi, K., Reue, K., Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am. J. Physiol. Endocrinol. Metab. 296:6 (2009), E1195–E1209.
79. [79] Keller, P., Petrie, J.T., De Rose, P., et al. Fat-specific protein 27 regulates storage of triacylglycerol. J. Biol. Chem. 283:21 (2008), 14355–14365.
80. [80] Wang, B., Hsu, S.H., Wang, X., et al. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. Hepatology 59:2 (2014), 555–566.
81. [81] Xu, Y., Xia, F., Ma, L., et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 310:2 (2011), 160–169.
82. [82] Hussain, M.M., Rava, P., Pan, X., et al. Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism. Curr. Opin. Lipidol. 19:3 (2008), 277–284.
83. [83] Soh, J., Iqbal, J., Queiroz, J., Fernandez-Hernando, C., Hussain, M.M., MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat. Med. 19:7 (2013), 892–900.
84. [84] Soh, J., Hussain, M.M., Supplementary site interactions are critical for the regulation of microsomal triglyceride transfer protein by microRNA-30c. Nutr. Metab. (Lond)., 10(1), 2013, 56.
85. [85] Zhang, D., Lu, K., Dong, Z., Jiang, G., Xu, W., Liu, W., The effect of exposure to a high-fat diet on microRNA expression in the liver of blunt snout bream (Megalobrama amblycephala). PLoS One., 9(5), 2014, e96132.
86. [86] Vickers, K.C., Moore, K.J., Small RNA overcomes the challenges of therapeutic targeting of microsomal triglyceride transfer protein. Circ. Res. 113:11 (2013), 1189–1191.
87. [87] Chapman, M.J., The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development. Curr. Med. Res. Opin. 21:Suppl 6 (2005), S17–S22.
88. [88] Vergeer, M., Holleboom, A.G., Kastelein, J.J., Kuivenhoven, J.A., The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?. J. Lipid Res. 51:8 (2010), 2058–2073.
89. [89] Horie, T., Ono, K., Horiguchi, M., et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc. Natl. Acad. Sci. U. S. A. 107:40 (2010), 17321–17326.
90. [90] Marquart, T.J., Allen, R.M., Ory, D.S., Baldan, A., miR-33 links SREBP-2 induction to repression of sterol transporters. Proc. Natl. Acad. Sci. U. S. A. 107:27 (2010), 12228–12232.
91. [91] Gerin, I., Clerbaux, L.A., Haumont, O., et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J. Biol. Chem. 285:44 (2010), 33652–33661.
92. [92] Rayner, K.J., Esau, C.C., Hussain, F.N., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478:7369 (2011), 404–407.
93. [93] Rayner, K.J., Sheedy, F.J., Esau, C.C., et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121:7 (2011), 2921–2931.
94. [94] Ouimet, M., Ediriweera, H.N., Gundra, U.M., et al. MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J. Clin. Invest., 2015, 2015.
95. [95] Sahoo, D., Trischuk, T.C., Chan, T., et al. ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes. J. Lipid Res. 45:6 (2004), 1122–1131.
96. [96] Horie, T., Baba, O., Kuwabara, Y., et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J. Am. Heart Assoc., 1(6), 2012, e003376.
97. [97] Goedeke, L., Salerno, A., Ramirez, C.M., et al. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol. Med. 6:9 (2014), 1133–1141.
98. [98] Marquart, T.J., Wu, J., Lusis, A.J., Baldan, A., Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 33:3 (2013), 455–458.
99. [99] Dai, Y., Wang, D., Tian, X., et al. Insights into the application of let-7 family as promising biomarker in cancer screening. Tumour Biol. 36:7 (2015), 5233–5239.
100. [100] Chen, C.Z., Li, L., Lodish, H.F., Bartel, D.P., MicroRNAs modulate hematopoietic lineage differentiation. Science 303:5654 (2004), 83–86.
101. [101] Vickers, K.C., Landstreet, S.R., Levin, M.G., et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc. Natl. Acad. Sci. U. S. A. 111:40 (2014), 14518–14523.
102. [102] Vickers, K.C., Remaley, A.T., HDL and cholesterol: life after the divorce?. J. Lipid Res. 55:1 (2014), 4–12.
103. [103] Schulte, C., Molz, S., Appelbaum, S., et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PLoS One., 10(12), 2015, e0145930.
104. [104] Finucane, M.M., Stevens, G.A., Cowan, M.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377:9765 (2011), 557–567.
105. [105] Mang, G.M., Pradervand, S., Du, N.H., et al. A neuron-specific deletion of the microRNA-processing enzyme DICER induces severe but transient obesity in mice. PLoS One, 10(1), 2015, e0116760.
106. [106] Wang, H., Luo, J., Zhang, T., et al. MicroRNA-26a/b and their host genes synergistically regulate triacylglycerol synthesis by targeting the INSIG1 gene. RNA Biol., 2016, 1–11.
107. [107] Fu, X., Dong, B., Tian, Y., et al. MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J. Clin. Invest. 125:6 (2015), 2497–2509.
108. [108] Gao, J., Liu, Q.G., The role of miR-26 in tumors and normal tissues (Review). Oncol. Lett. 2:6 (2011), 1019–1023.
109. [109] Icli, B., Wara, A.K., Moslehi, J., et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ. Res. 113:11 (2013), 1231–1241.
110. [110] Wei, C., Kim, I.K., Kumar, S., et al. NF-kappaB mediated miR-26a regulation in cardiac fibrosis. J. Cell Physiol. 228:7 (2013), 1433–1442.
111. [111] Leeper, N.J., Cooke, J.P., MicroRNA and mechanisms of impaired angiogenesis in diabetes mellitus. Circulation 123:3 (2011), 236–238.
112. [112] Jansen, F., Wang, H., Przybilla, D., et al. Vascular endothelial microparticles-incorporated microRNAs are altered in patients with diabetes mellitus. Cardiovasc Diabetol., 15(1), 2016, 49.
113. [113] Guay, C., Menoud, V., Rome, S., Regazzi, R., Horizontal transfer of exosomal microRNAs transduce apoptotic signals between pancreatic beta-cells. Cell Commun. Signal., 13, 2015, 17.
114. [114] Finnerty, J.R., Wang, W.X., Hebert, S.S., Wilfred, B.R., Mao, G., Nelson, P.T., The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J. Mol. Biol. 402:3 (2010), 491–509.
115. [115] Trajkovski, M., Hausser, J., Soutschek, J., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474:7353 (2011), 649–653.
116. [116] Xie, H., Lim, B., Lodish, H.F., MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 58:5 (2009), 1050–1057.
117. [117] Xie, H., Sun, L., Lodish, H.F., Targeting microRNAs in obesity. Expert Opin. Ther. Targets. 13:10 (2009), 1227–1238.
118. [118] Fichtlscherer, S., De Rosa, S., Fox, H., et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 107:5 (2010), 677–684.
119. [119] Rayner, K.J., Moore, K.J., MicroRNA control of high-density lipoprotein metabolism and function. Circ. Res. 114:1 (2014), 183–192.
120. [120] Boettger, T., Beetz, N., Kostin, S., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J. Clin. Invest. 119:9 (2009), 2634–2647.
121. [121] Cordes, K.R., Sheehy, N.T., White, M.P., et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460:7256 (2009), 705–710.
122. [122] Xin, M., Small, E.M., Sutherland, L.B., et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 23:18 (2009), 2166–2178.
123. [123] Wei, Y., Nazari-Jahantigh, M., Neth, P., Weber, C., Schober, A., MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?. Arterioscler. Thromb. Vasc. Biol. 33:3 (2013), 449–454.
124. [124] Takanabe, R., Ono, K., Abe, Y., et al. Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem. Biophys. Res. Commun. 376:4 (2008), 728–732.
125. [125] Jordan, S.D., Kruger, M., Willmes, D.M., et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat. Cell Biol. 13:4 (2011), 434–446.
126. [126] Kornfeld, J.W., Baitzel, C., Konner, A.C., et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 494:7435 (2013), 111–115.
127. [127] Quan, X., Zhang, L., Li, Y., Liang, C., TCF2 attenuates FFA-induced damage in islet beta-cells by regulating production of insulin and ROS. Int. J. Mol. Sci. 15:8 (2014), 13317–13332.
128. [128] Kraus, W.E., Bittner, V., Appel, L., et al. The National Physical Activity Plan: a call to action from the American Heart Association: a science advisory from the American Heart Association. Circulation 131:21 (2015), 1932–1940.
129. [129] Melo, S.F., Fernandes, T., Barauna, V.G., et al. Expression of MicroRNA-29 and collagen in cardiac muscle after swimming training in myocardial-infarcted rats. Cell Physiol. Biochem. 33:3 (2014), 657–669.
130. [130] Nielsen, S., Akerstrom, T., Rinnov, A., et al. The miRNA plasma signature in response to acute aerobic exercise and endurance training. PLoS One, 9(2), 2014, e87308.
131. [131] Ringholm, S., Bienso, R.S., Kiilerich, K., et al. Bed rest reduces metabolic protein content and abolishes exercise-induced mRNA responses in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 301:4 (2011), E649–E658.
132. [132] Xue, Y., Wei, Z., Ding, H., et al. MicroRNA-19b/221/222 induces endothelial cell dysfunction via suppression of PGC-1alpha in the progression of atherosclerosis. Atherosclerosis 241:2 (2015), 671–681.
133. [133] Dentelli, P., Rosso, A., Orso, F., Olgasi, C., Taverna, D., Brizzi, M.F., microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler. Thromb. Vasc. Biol. 30:8 (2010), 1562–1568.
134. [134] Minami, Y., Satoh, M., Maesawa, C., et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur. J. Clin. Invest. 39:5 (2009), 359–367.
135. [135] Bye, A., Rosjo, H., Aspenes, S.T., Condorelli, G., Omland, T., Wisloff, U., Circulating microRNAs and aerobic fitness–the HUNT-Study. PLoS One, 8(2), 2013, e57496.
136. [136] Baggish, A.L., Hale, A., Weiner, R.B., et al. Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J. Physiol. 589:Pt 16 (2011), 3983–3994.
137. [137] Costa, M.C., Leitao, A.L., Enguita, F.J., MicroRNA profiling in plasma or serum using quantitative RT-PCR. Methods Mol. Biol. 1182 (2014), 121–129.
138. [138] Cheng, Y., Tan, N., Yang, J., et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin. Sci. (Lond). 119:2 (2010), 87–95.
139. [139] Wahlestedt, C., Salmi, P., Good, L., et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U. S. A. 97:10 (2000), 5633–5638.
140. [140] Yoo, B.H., Bochkareva, E., Bochkarev, A., Mou, T.C., Gray, D.M., 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res. 32:6 (2004), 2008–2016.
141. [141] Bianchini, D., Omlin, A., Pezaro, C., et al. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br. J. Cancer. 109:10 (2013), 2579–2586.
142. [142] Janssen, H.L., Reesink, H.W., Lawitz, E.J., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368:18 (2013), 1685–1694.
143. [143] Lindow, M., Kauppinen, S., Discovering the first microRNA-targeted drug. J. Cell Biol. 199:3 (2012), 407–412.
144. [144] Bouchie, A., First microRNA mimic enters clinic. Nat. Biotechnol., 31(7), 2013, 577.
145. [145] Tutar, L., Tutar, E., Ozgur, A., Tutar, Y., Therapeutic targeting of microRNAs in Cancer: future perspectives. Drug Dev. Res. 76:7 (2015), 382–388.
146. [146] Jung, E.J., Santarpia, L., Kim, J., et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118:10 (2012), 2603–2614.